Corpus Intelligence IC Memo — HOSPITAL METROPOLITANO 2026-04-26 05:22 UTC
IC Memo — HOSPITAL METROPOLITANO
Investment Committee Memorandum | PR | 132 beds | Grade C | EBITDA uplift $3.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HOSPITAL METROPOLITANO

CCN 400106 | nan, PR | 132 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HOSPITAL METROPOLITANO is a 132-bed safety-net/medicaid heavy in nan, PR with $48.1M in net patient revenue and a -4.4% operating margin. The hospital serves a payer mix of 8.4% Medicare, 28.5% Medicaid, and 63.2% commercial.

Thesis: Undervalued. Our ML models identify $3.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -4.4% to 3.0% (+736bps).

Net Revenue HCRIS$48.1M
Current EBITDA COMPUTED$-2.1M
Operating Margin COMPUTED-4.4%
Occupancy HCRIS44.7%
Revenue / Bed COMPUTED$364K
Net-to-Gross HCRIS61.3%
Distress Probability ML59.3%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
39
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -4.4% places it above the state median. Among 39 size-comparable peers (66-264 beds), the median margin is -7.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (66-264), prioritizing same-state peers. 39 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HOSPITAL METROPOLITANO (Target)PR132$48.1M-4.4%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
HOSPITAL DR. ALEJANDRO OTEROPR263$129.0M-1.0%
HOSPITAL MENONITA CAGUAS INCPR232$114.1M6.8%
DOCTOR CENTER HOSPITAL MANATI PR258$103.4M1.6%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
UNIVERSITY DISCTRICT HOSPITALPR210$97.4M-43.2%
HOSPITAL MENONITA AIBONITOPR129$92.1M-3.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.0M+210bp18mo
Cost to Collect4.5%2.5%$961K+200bp12mo
Denial Rate Reduction12.0%6.5%$952K+198bp12mo
A/R Days Reduction5200.0%3800.0%$585K+122bp9mo
Clean Claim Rate88.0%96.0%$31K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.0M
Cost to Collect
$961K
Denial Rate Reduction
$952K
A/R Days Reduction
$585K
Clean Claim Rate
$31K
Total EBITDA Uplift$3.5M
Current EBITDA$-2.1M
+ RCM Uplift+$3.5M
Pro Forma EBITDA$1.4M
Current Margin-4.4%
Pro Forma Margin3.0%
WC Released (1x)$1.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-3.2M$21.5M0.00x-100.0%
Base (11x exit)10.0x11.0x$-3.2M$22.6M0.00x-100.0%
Bull Case9.0x11.0x$-2.9M$33.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.9M$35.4M0.00x-100.0%
Bear Case11.0x10.0x$-3.6M$4.9M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-3.6M$4.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (28.5%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 59.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 39 hospitals with 66-264 beds
  • Same-state prioritization (n=40)
  • Comp margins: P25=-19.7% / P50=-7.1% / P75=1.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.